Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference
Seres Therapeutics (MCRB) announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, where CEO Eric Shaff will present on January 16, 2025. The presentation will focus on the company's biotherapeutics pipeline, particularly SER-155, which recently received FDA Breakthrough Therapy designation for reducing bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant.
The Phase 1b study results showed SER-155 achieved a 77% relative risk reduction in bloodstream infections, significant reduction in antibiotic exposure, and lower febrile neutropenia incidence. Seres is actively seeking partners to explore SER-155's development for additional vulnerable populations, including autologous-HSCT patients, cancer patients, CAR-T recipients, and others.
Seres Therapeutics (MCRB) ha annunciato la sua partecipazione alla 43ª Conferenza Sanitaria Annuale J.P. Morgan, dove il CEO Eric Shaff presenterà il 16 gennaio 2025. La presentazione si concentrerà sul pipeline di bioterapici dell'azienda, in particolare su SER-155, che ha recentemente ricevuto la designazione di Terapia Innovativa da parte della FDA per ridurre le infezioni del flusso sanguigno negli adulti sottoposti a trapianto di cellule staminali ematopoietiche allogeniche.
I risultati dello studio di Fase 1b hanno dimostrato che SER-155 ha raggiunto una riduzione relativa del rischio del 77% nelle infezioni del flusso sanguigno, una significativa riduzione dell'esposizione agli antibiotici e una minore incidenza di neutropenia febbrile. Seres sta attivamente cercando partner per esplorare lo sviluppo di SER-155 per ulteriori popolazioni vulnerabili, inclusi pazienti sottoposti a HSCT autologo, pazienti oncologici, riceventi di CAR-T e altri.
Seres Therapeutics (MCRB) anunció su participación en la 43ª Conferencia Anual de Salud J.P. Morgan, donde el CEO Eric Shaff presentará el 16 de enero de 2025. La presentación se centrará en la línea de bioterapéuticos de la compañía, especialmente en SER-155, que recientemente recibió la designación de Terapia Innovadora por parte de la FDA para reducir las infecciones en el torrente sanguíneo en adultos que se someten a un trasplante de células madre hematopoyéticas alogénicas.
Los resultados del estudio de Fase 1b mostraron que SER-155 logró una reducción del riesgo relativo del 77% en infecciones en el torrente sanguíneo, una reducción significativa en la exposición a antibióticos y una menor incidencia de neutropenia febril. Seres está buscando activamente socios para explorar el desarrollo de SER-155 para poblaciones vulnerables adicionales, incluidos pacientes de HSCT autólogo, pacientes con cáncer, receptores de CAR-T y otros.
Seres Therapeutics (MCRB)는 제43회 J.P. Morgan 헬스케어 컨퍼런스에 참여한다고 발표했으며, CEO 에릭 샤프가 2025년 1월 16일에 발표할 예정이다. 이 발표는 회사의 생물치료제 파이프라인, 특히 SER-155에 초점을 맞출 것이며, 이는 최근 FDA 혁신 치료제 지정을 받아 알로겐적 조혈 줄기 세포 이식을 받는 성인의 혈류 감염을 줄이는 데 도움을 준다.
1b상 연구 결과에 따르면 SER-155는 혈류 감염에서 77% 상대적 위험 감소를 달성했으며, 항생제 노출의 상당한 감소와 발열성 호중구 감소증의 발생률 감소를 보였다. Seres는 자가 HSCT 환자, 암 환자, CAR-T 수혜자 등 추가적인 취약한 인구 집단을 위한 SER-155의 개발을 탐색하기 위해 적극적으로 파트너를 찾고 있다.
Seres Therapeutics (MCRB) a annoncé sa participation à la 43e Conférence annuelle sur la santé J.P. Morgan, où le PDG Eric Shaff présentera le 16 janvier 2025. La présentation mettra l'accent sur le pipeline de biothérapeutiques de l'entreprise, en particulier SER-155, qui a récemment reçu la désignation de thérapie innovante par la FDA pour réduire les infections sanguines chez les adultes subissant une greffe de cellules souches hématopoïétiques allogéniques.
Les résultats de l'étude de phase 1b ont montré que SER-155 a atteint une réduction du risque relatif de 77% des infections sanguines, une réduction significative de l'exposition aux antibiotiques et une incidence plus faible de neutropénie fébrile. Seres recherche activement des partenaires pour explorer le développement de SER-155 pour d'autres populations vulnérables, y compris les patients ayant subi une HSCT autologue, les patients atteints de cancer, les receveurs de CAR-T et d'autres.
Seres Therapeutics (MCRB) gab die Teilnahme an der 43. jährlichen J.P. Morgan Healthcare-Konferenz bekannt, bei der CEO Eric Shaff am 16. Januar 2025 einen Vortrag halten wird. Die Präsentation wird sich auf die Biotherapeutika-Pipeline des Unternehmens konzentrieren, insbesondere auf SER-155, das kürzlich von der FDA die Breakthrough-Therapie-Bezeichnung erhalten hat, um Blutstrominfektionen bei Erwachsenen, die sich einer allogenen hämatopoetischen Stammzelltransplantation unterziehen, zu reduzieren.
Die Ergebnisse der Phase 1b-Studie zeigten, dass SER-155 eine 77% relative Risikominderung bei Blutstrominfektionen erreichte, eine signifikante Reduzierung der Antibiotikaexposition und eine geringere Inzidenz von febriler Neutropenie. Seres sucht aktiv nach Partnern, um die Entwicklung von SER-155 für weitere gefährdete Bevölkerungsgruppen zu erkunden, einschließlich Patienten mit autologischer HSCT, Krebspatienten, CAR-T-Empfängern und anderen.
- None.
- None.
CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will participate in the 43rd Annual J.P. Morgan Healthcare Conference. Eric Shaff, President and Chief Executive Officer, will present a corporate overview on January 16, 2025 at 7:30 a.m. PT.
Seres will highlight its plans to advance its biotherapeutics pipeline, focusing on SER-155, the Company’s lead program. The Company recently announced that SER-155 received Breakthrough Therapy designation for the reduction of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant, to treat hematological malignancies, from the US Food and Drug Administration (FDA). This designation was supported by Phase 1b placebo-controlled study results in patients undergoing allo-HSCT demonstrating that SER-155 was associated with a significant reduction in BSIs (
A live video webcast of the presentation will be accessible under the “Events and Presentations” tab on the “Investors and News” section of the Company’s website at www.serestherapeutics.com and will be available for replay following the event.
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. Seres led the successful development and approval of VOWST™, the first FDA-approved orally administered microbiome therapeutic, which was sold to Nestlé Health Science in September 2024. The Company is developing SER-155, which has received both Breakthrough Therapy and Fast Track designation, and which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a clinical study in patients undergoing allo-HSCT. SER-155 and the Company's other pipeline programs are designed to target multiple disease-relevant pathways and are manufactured from standard clonal cell banks via cultivation, rather than from the donor-sourced production process used for VOWST. In addition to allo-HSCT, the Company intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically vulnerable patient populations including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities. For more information, please visit www.serestherapeutics.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements about: our clinical development plans; the ability for SER-155 and other product candidates to improve patient outcomes in medically vulnerable populations; our ability to secure a partnership and/or generate additional capital; and other statements which are not historical fact.
These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: (1) we have incurred significant losses, are not currently profitable and may never become profitable; (2) our need for additional funding; (3) our history of operating losses; (4) our novel approach to therapeutic intervention; (5) our reliance on third parties to conduct our clinical trials and manufacture our product candidates; (6) the competition we will face; (7) our ability to protect our intellectual property; (8) our ability to retain key personnel and to manage our growth; (9) the effect of the VOWST sale on our ability to retain and hire key personnel and maintain relationships with our customers, suppliers, advertisers, partners and others with whom we do business, or on our operating results and businesses generally; (10) the risks associated with the disruption of management’s attention from ongoing business operations due to the obligation to provide transition services; (11) our failure to receive the installment payments or the milestone payments in the future; (12) the uncertainty of impact of the 50/50 profit and loss sharing arrangement on our reported results and liquidity; and (13) we may not be able to realize the anticipated benefits of the VOWST sale. These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC), on November 13, 2024, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Investor and Media Contacts:
IR@serestherapeutics.com
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com
FAQ
What results did SER-155 show in Seres Therapeutics' Phase 1b study for MCRB?
When will Seres Therapeutics (MCRB) present at the J.P. Morgan Healthcare Conference 2025?
What breakthrough designation did MCRB's SER-155 receive from the FDA?
What additional patient populations could benefit from MCRB's SER-155 treatment?
What is Seres Therapeutics (MCRB) seeking regarding SER-155 development?
